跳至主要内容
临床试验/NCT02734459
NCT02734459已完成3 期

A Multi Center, Open Label, Randomized, Two- Treatment, Single Dose, Crossover, Bioequivalence Study To Compare The Pharmacokinetics Of Marketed Product TobraDex® (Tobramycin And Dexamethasone Ophthalmic Ointment) To An Experimental Ophthalmic Sterile Ointment Containing Tobramycin 0.3% And Dexamethasone 0.1% W/W In Aqueous Humor In Patients Undergoing Indicated Cataract Surgery

Semler Research Center Pvt. Ltd.0 个研究点目标入组 756 人开始时间: 2013年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
756
主要终点
Concentration of dexamethasone in aqueous humor at different time points after administration of a single dose of each of the two drugs.

研究概览

简要总结

Each patient will be randomized to receive one dose of the test article in one eye and one dose of the reference formulations in the contralateral eye. One eye will be selected as the initial eye for cataract surgery and aqueous humor collection and hence will be dosed and operated on first. Followed by the second eye which will be dosed no early than a week followed by aqueous humor collection as per specified time points and no later than 35 days following the first eye again prior to the cataract surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Be male or female 18 years of age and above
  • Presence of visually significant cataracts in both eyes
  • Have a chief complaint consistent with visually significant cataracts
  • Be able to communicate effectively with the study personnel and be able to understand and follow directions
  • Be medically fit with clinically acceptable laboratory profiles and ECG
  • Be willing to carry out the required pre op directions and post op care and be able to make the scheduled appointment
  • Have given the written informed consent for participation in the study
  • In addition, female patients of child bearing potential age must have a negative urine pregnancy test

排除标准

  • Participation in any ophthalmic indicative bioavailability/ bioequivalence/ Pharmacokinetic study or received an ophthalmic indicative investigational drug within a period of three months prior to screening
  • Presence or history of recent viral corneal disorder or active corneal condition which is contraindicated.
  • Presence or history of uveitis or uveitis
  • Presence of retinal disorders
  • Ocular trauma within three months of the trial
  • Patients who had received topical and or systemic/ oral steroids
  • Uncontrolled diabetes
  • History of any allergies
  • Known hypersensitivity or allergy to TobraDex® in combination or its components
  • Clinical laboratory test values outside the acceptable reference range and when confirmed on re-examination deemed to be clinically significant as determined by the investigator(s)
  • Clinically significant illness during 3 weeks prior to Visit 1 (as determined by the investigators)
  • Presence of a clinically significant systemic disorder

研究组 & 干预措施

tobramycin and dexamethasone ophthalmic test ointment

Experimental

The test drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in one eye before the cataract surgery.

干预措施: cataract surgery (Drug)

TobraDex® ointment

Active Comparator

The reference drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in another eye before the cataract surgery.

干预措施: cataract surgery (Drug)

结局指标

主要结局

Concentration of dexamethasone in aqueous humor at different time points after administration of a single dose of each of the two drugs.

时间窗: 30 min - 8 hours

A series of aqueous humor samples will be collected from each eye of each patient.

次要结局

未报告次要终点

研究者

发起方
Semler Research Center Pvt. Ltd.
申办方类型
Industry
责任方
Sponsor

相似试验

已完成
不适用
Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With a Hybrid-Fractional Laser for Facial RejuvenationWrinkleSkin LaxityPhotoaging
NCT06436261Revision Skincare20
进行中(未招募)
1 期
A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative colitis
EUCTR2016-001833-29-NLGlaxoSmithKline Research & Development Ltd36
进行中(未招募)
1 期
A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with moderate to severe rheumatoid arthritis.
EUCTR2016-000912-13-GBGlaxoSmithKline Research & Development Ltd52
进行中(未招募)
1 期
A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative colitisActive ulcerative colitisMedDRA version: 20.0Level: HLGTClassification code 10017969Term: Gastrointestinal inflammatory conditionsSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2016-001833-29-SEGlaxoSmithKline Research & Development Ltd36
已完成
2 期
A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative colitis (study 202152)10017969ulcerative colitis
NL-OMON45582GlaxoSmithKline3